HER2-Negative Breast Cancer Market to Witness Promising Upswing by 2032, DelveInsight Forecasts

DelveInsight's "HER2-Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the HER2-Negative Breast Cancer, historical and forecasted epidemiology as well as the HER2-Negative Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the HER2-Negative Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; HER2-Negative Breast Cancer Market Forecast
https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the HER2-Negative Breast Cancer Market Report:
• The HER2-Negative Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032).
• In April 2025, AstraZeneca has reported encouraging topline interim findings from SERENA-6, a randomized, multicenter, double-blind Phase III study. The trial assessed camizestrant, the company's investigational next-generation oral selective estrogen receptor degrader (SERD), in combination with one of three cyclin-dependent kinase (CDK) 4/6 inhibitors-Pfizer's Ibrance, Eli Lilly's Verzenio, or Novartis' Kisqali-compared to the standard-of-care, an aromatase inhibitor plus a CDK4/6 inhibitor, as first-line therapy for patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer harboring an estrogen receptor alpha (ESR1) mutation. Since ESR1 mutations are a major resistance mechanism arising during or after endocrine therapy, liquid biopsy testing for these mutations has become standard clinical practice.
• The US experienced 253,465 new instances of breast cancer in 2020, according to the Global Cancer Observatory (2020)
• According to data from Surveillance, Epidemiology and End Results (SEER, n.d.), the US female population experiences the diagnosis of more than 200,000 new instances of breast cancer each year
• According to the Global Cancer Observatory (2020), there were 69,697 new cases of breast cancer in Germany, France, Italy, Spain, and the United Kingdom, respectively, in 2020
• Key HER2-Negative Breast Cancer Companies: Genentech, Inc., AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai Inc., Novartis Pharmaceuticals, Adagene Inc, Jiangsu HengRui Medicine Co., Ltd, Pfizer, Novartis, CytomX Therapeutics, Tyme, Inc, Puma Biotechnology, Inc., G1 Therapeutics, Inc., Context Therapeutics Inc., and others
• Key HER2-Negative Breast Cancer Therapies: Paclitaxel, Doxorubicin, AZD9833, Pembrolizumab, TF2 - 68 Ga-IMP-288, BGB-290, Eribulin, Dapagliflozin, ADG106, Famitinib Malate, Talazoparib Tosylate, Letrozole, CX-2009, SM-88, Neratinib, G1T38, Onapristone, and others
• The HER2-Negative Breast Cancer epidemiology based on gender analyzed that HER2-negative breast cancer mainly develops in older women
• The HER2-Negative Breast Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage HER2-Negative Breast Cancer pipeline products will significantly revolutionize the HER2-Negative Breast Cancer market dynamics.

HER2-Negative Breast Cancer Overview
Breast cancer begins when aberrant malignant cells proliferate uncontrollably and rise in number, forming a tumour. The ducts or lobules of the breast are where it typically begins. Numerous signals are sent to cancer cells, causing them to proliferate. Hormones may be one of these messages.

Get a Free sample for the HER2-Negative Breast Cancer Market Report
https://www.delveinsight.com/report-store/her2-negative-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

HER2-Negative Breast Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

HER2-Negative Breast Cancer Epidemiology Segmentation:
The HER2-Negative Breast Cancer market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of HER2-Negative Breast Cancer
• Prevalent Cases of HER2-Negative Breast Cancer by severity
• Gender-specific Prevalence of HER2-Negative Breast Cancer
• Diagnosed Cases of Episodic and Chronic HER2-Negative Breast Cancer

Download the report to understand which factors are driving HER2-Negative Breast Cancer epidemiology trends @ HER2-Negative Breast Cancer Epidemiology Forecast
https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

HER2-Negative Breast Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the HER2-Negative Breast Cancer market or expected to get launched during the study period. The analysis covers HER2-Negative Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the HER2-Negative Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

HER2-Negative Breast Cancer Therapies and Key Companies
• Paclitaxel: Dana-Farber Cancer Institute
• Doxorubicin: Genentech, Inc.
• AZD9833: AstraZeneca
• Pembrolizumab: Merck Sharp & Dohme LLC
• TF2 - 68 Ga-IMP-288: Gilead Sciences
• BGB-290: BeiGene
• Eribulin: Eisai Inc.
• Dapagliflozin: Novartis Pharmaceuticals
• ADG106: Adagene Inc
• Famitinib Malate: Jiangsu HengRui Medicine Co., Ltd
• Talazoparib Tosylate: Pfizer
• Letrozole: Novartis
• CX-2009: CytomX Therapeutics
• SM-88: Tyme, Inc
• Neratinib: Puma Biotechnology, Inc.
• G1T38: G1 Therapeutics, Inc.
• Onapristone: Context Therapeutics Inc.

Discover more about therapies set to grab major HER2-Negative Breast Cancer market share @ HER2-Negative Breast Cancer Treatment Market
https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the HER2-Negative Breast Cancer Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key HER2-Negative Breast Cancer Companies: Genentech, Inc., AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai Inc., Novartis Pharmaceuticals, Adagene Inc, Jiangsu HengRui Medicine Co., Ltd, Pfizer, Novartis, CytomX Therapeutics, Tyme, Inc, Puma Biotechnology, Inc., G1 Therapeutics, Inc., Context Therapeutics Inc., and others
• Key HER2-Negative Breast Cancer Therapies: Paclitaxel, Doxorubicin, AZD9833, Pembrolizumab, TF2 - 68 Ga-IMP-288, BGB-290, Eribulin, Dapagliflozin, ADG106, Famitinib Malate, Talazoparib Tosylate, Letrozole, CX-2009, SM-88, Neratinib, G1T38, Onapristone, and others
• HER2-Negative Breast Cancer Therapeutic Assessment: HER2-Negative Breast Cancer current marketed and HER2-Negative Breast Cancer emerging therapies
• HER2-Negative Breast Cancer Market Dynamics: HER2-Negative Breast Cancer market drivers and HER2-Negative Breast Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• HER2-Negative Breast Cancer Unmet Needs, KOL's views, Analyst's views, HER2-Negative Breast Cancer Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.